Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer
European Journal of Clinical Pharmacology · 2024-09 · 80 (9) · 1387-1397
DOI: 10.1007/s00228-024-03715-4 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 20.06.2024. Verfasst von Meiyu Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2- metastatic breast cancer. METHODS: A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3-4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. RESULTS: This study included 44 arms from 48 publications, with a total sample size of 7881 patients. Our study revealed that CDK4/6 inhibitors had a median OS of 40.7 months, a median PFS of 14.8 months, and an ORR of 40%, whereas PI3K/AKT/mTOR inhibitors had a median OS of 29.8 months, a median PFS of 8.3 months, and an ORR of 20%. Additionally, this study also found that the proportion of patients with visceral metastases and specific endocrine therapy used in combination significantly impact OS and PFS. In terms of adverse events, CDK4/6 inhibitors exhibited a relatively high incidence of hematological adverse events. CONCLUSION: Our study provides solid quantitative evidence for the first-line recommendation of CDK4/6 inhibitors combined with endocrine therapy for ER+/HER2- metastatic breast cancer in clinical guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, China Pharmaceutical University, Nanjing, China.
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. jean0129@163.com.
- School of Pharmacy, China Pharmaceutical University, Nanjing, China. cpu_yj@163.com.
- Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China. cpu_yj@163.com.
Zitieren
APA
Pan, M., Lin, Y., Liu, Y., Xu, R., & Yang, J. (2024). Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer. European Journal of Clinical Pharmacology, 80(9), 1387-1397. https://doi.org/10.1007/s00228-024-03715-4
Vancouver
Pan M, Lin Y, Liu Y, Xu R, Yang J. Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer. European Journal of Clinical Pharmacology. 2024;80(9):1387-1397. doi:10.1007/s00228-024-03715-4
BibTeX
@article{Pan2024,
author = {Pan, Meiyu and Lin, Yan and Liu, Yinhui and Xu, Ruijuan and Yang, Jin},
title = {Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
volume = {80},
number = {9},
pages = {1387--1397},
doi = {10.1007/s00228-024-03715-4}
}
EUVIMED